@mrs.fitskns's peptide weight loss claims, fact-checked

What did @mrs.fitskns actually say?

The creator promoted a compound she calls "reda" as something that "hits a couple different receptors" like a "GLP3," crediting it for dropping her from 140 to 120 pounds over roughly two months. She said it took four weeks to kick in, caused fewer side effects than "churzepatay" (tirzepatide), and that her husband actually owns the company she is recommending. She offered a discount code and directed viewers to fitskinspeptides.com, which she openly called a "gray market company."

So we have a seller with a direct financial stake, a personal testimonial, a coupon code, and a compound most viewers have never heard of, all packaged as casual peer advice. That combination warrants a close look.

Does the science back this up?

"Reda" does not match any approved drug or well-documented peptide name. The most plausible candidate based on context is retatrutide, a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, currently in Phase 3 trials by Eli Lilly. It is not approved. It is not legally available outside clinical trials.

That said, the underlying science is real. Jastreboff et al. (2023, New England Journal of Medicine) reported up to 24.2% mean body weight reduction in a Phase 2 retatrutide trial over 48 weeks, which is a significant result by any standard. The mechanism she gestures at, multiple receptor targets, is directionally correct. But she calls it a "GLP3," which is not a pharmacological classification. The receptors are GLP-1, GIP, and glucagon. She is explaining mechanism from memory, not from understanding.

What did they get wrong (or right)?

Wrong: The "gray market but we test it" framing is a false reassurance. Purity testing confirms identity and concentration at a single point. It does not cover sterility, bacterial endotoxins, particulate matter, or whether the vial-to-vial dosing is consistent. Legalov et al. (2022, Drug Testing and Analysis) found significant quality variation in peptides from unregulated online vendors even when vendors claimed third-party testing. "99% purity" is a marketing number, not a safety certificate.

Wrong: Framing an unapproved Phase 3 compound as something you should just "try" with a coupon code is genuinely irresponsible. The Phase 2 data that makes retatrutide exciting was generated under controlled clinical conditions with pharmaceutical-grade material and medical supervision.

Right: She does correctly flag digestive side effects, protein intake, and hydration, all consistent with GLP-1 class drug literature. She also discloses the financial relationship upfront, which is more transparency than most influencer peptide promotions offer.

What should you actually know?

Retatrutide, if that is what this product is, is not FDA-approved and is not legally available for human use outside of clinical trials. Purchasing it from an unregulated website, regardless of how fast it ships, carries real risks: unknown actual dosing, contamination, zero medical oversight, and no legal recourse if something goes wrong.

The creator lost 20 pounds and attributes it to reda. That is one data point from someone who profits from selling the product. It is not clinical evidence, and weight loss from a GLP-1 class compound does not isolate the variable cleanly anyway, since diet changes typically follow appetite suppression.

If you are interested in GLP-1 class therapies for weight management, the path that actually protects you runs through a licensed provider who can review your health history, monitor labs, and adjust your treatment. Self-administering an unapproved triple receptor agonist purchased from a gray-market site is not optimization. It is an uncontrolled experiment with no safety net and no one accountable if it goes wrong.